Printer Friendly

SOMANETICS ANNOUNCES CLEARANCE TO MARKET INVOS 3100 CEREBRAL OXIMETER

SOMANETICS ANNOUNCES CLEARANCE TO MARKET INVOS 3100 CEREBRAL OXIMETER
 TROY, Mich., July 6 /PRNewswire/ -- Somanetics Corporation (NASDAQ: SMTS) today announced that its INVOS(R) 3100 Cerebral Oximeter has been cleared for marketing, promotion and commercial sales.
 Somanetics' INVOS 3100 Cerebral Oximeter is the first product of its kind to monitor, directly, continuously and non-invasively, the oxygen saturation of the blood in portions of an adult's brain. It utilizes In Vivo Optical Spectroscopy (INVOS(R)) technology which may be used to quantify various characteristics of human blood and tissue, by measuring low-intensity visible and near infrared light -- virtually eliminating the extraneous information around the brain caused by surrounding bone, muscle and other tissue.
 "INVOS technology provides information from the brain that could not previously be analyzed using optical spectroscopy," said Dr. James Ausman, professor and head of the department of neurosurgery at the University of Illinois' College of Medicine at Chicago. "Until now, we had no way of measuring oxygen levels in the brain. It was like looking at a car 50 feet away and trying to determine whether the spark plug or transmission had failed. This machine is the equivalent of a listening device we can put directly on the hood to actually find out the source of the problem."
 The brain is the human organ least tolerant of oxygen deprivation. Without sufficient oxygen, brain cells die within minutes, possibly resulting in paralysis, severe and complex disabilities, irreversible brain damage or death. The immediate, sensitive information Somanetics' INVOS 3100 Cerebral Oximeter provides is expected to help surgeons, anesthesiologists and other medical personnel take early corrective action when needed.
 "The INVOS 3100 Cerebral Oximeter provides the medical community with a window to the brain," said Gary D. Lewis, chairman, president and chief executive officer of Somanetics, and primary inventor of the device. "To have an opportunity to introduce this new technology to the world and -- more importantly -- to help save lives along the way is very exciting. It's an equally exciting time for our company as well, as it begins to transcend from its development stage to a dynamic, operating organization."
 The INVOS 3100 Cerebral Oximeter is a compact, portable monitor consisting of a small disposable sensor (SomaSensor(TM)) that transmits and receives light, a computer to analyze the data and a monitor to display the results. As Cerebral Oximeters are delivered into the marketplace, the company expects the SomaSensors to become an increasingly important portion of its sales.
 Somanetics has established a global distribution network for the INVOS 3100 Cerebral Oximeter including distributors in the U.S., Argentina, Australia, and New Zealand, Canada, Italy, Japan, Korea, the Netherlands and the United Kingdom. The sales and specialty network is expected to continue to expand as the product is introduced to hospitals' operating rooms, emergency rooms, recovery rooms, and intensive-care units. With an initial target market of approximately 26,000 adult critical care sites, composed mostly of operating rooms and intensive care beds, in the U.S. alone, Somanetics' new device holds outstanding market potential.
 The company expects to identify other applications for INVOS technology and develop additional products accordingly. Initial research and development efforts are focused on developing product extensions of the adult Cerebral Oximeter for use on children and newborns.
 Somanetics Corporation is headquartered in Troy and has 40 employees. The company develops, manufactures and markets computer- based medical diagnostic and monitoring equipment using In Vivo Optical Spectroscopy (INVOS(R)) technology.
 The company's common shares and Class B Warrants are publicly traded on NASDAQ under the symbols SMTS and SMTSZ, respectively.
 -0- 7/6/92
 /NOTE: A full media package with photos and fact sheets is available by overnight mail from CONTACT: Mary Ann Robb, 313-689-3996, or Mike Ard, 313-689-3050, both of Somanetics Corporation/
 (SMTS) CO: Somanetics Corporation ST: Michigan IN: MTC SU: PDT


DH -- DE006 -- 6544 07/06/92 10:18 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1992
Words:643
Previous Article:BRITISH AIRWAYS ANNOUNCES JUNE 1992 PRELIMINARY TRAFFIC AND CAPACITY STATISTICS
Next Article:DAYTON HUDSON, CHILD CARE GROUPS TO LAUNCH "CHILD CARE AWARE" PUBLIC CAMPAIGN ON CHILD CARE QUALITY
Topics:


Related Articles
SOMANETICS CORPORATION ANNOUNCES FISCAL SECOND-QUARTER RESULTS
'OUTSIDE LOOKING IN' -- A WINDOW TO THE BRAIN
SOMANETICS CORPORATION SECURITIES WILL TRADE IN NASDAQ NATIONAL MARKET
SOMANETICS ANNOUNCES THIRD-QUARTER RESULTS
SOMANETICS ANNOUNCES PATENT AWARD
SOMANETICS WINS LEADING EDGE TECHNOLOGIES AWARD
SOMANETICS CORPORATION ANNOUNCES YEAR-END RESULTS
Somanetics Announces International Introduction of the Next Generation Cerebral Oximeter Patient Monitoring System
Somanetics Announces Approval to Market Invos 4100 Cerebral Oximeter in Japan.
Somanetics Announces New FDA 510(K) Clearance.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters